Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 1,032

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

Open access
Furie, Richard, Rovin, Brad H., Houssiau, Frédéric, Malvar, Ana, Teng, Y.K. Onno, Contreras, Gabriel, Amoura, Zahir, Yu, Xueqing, Mok, Chi-Chiu, Santiago, Mittermayer B., Saxena, Amit, Green, Yulia, Ji, Beulah, Kleoudis, Christi, Burriss, Susan W., Barnett, Carly, Roth, David A. · 2020 · New England Journal of Medicine

Abstract

BACKGROUND: In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide-azathioprine), are unknown. METHODS: , and no use of rescue therapy). The time to a renal-related event or death was assessed. RESULTS: A total of 448 patients underwent randomization (224 to the belimumab group and 224 to the placebo group). At week 104, significantly more patients in the belimumab group than in the placebo group had a primary efficacy renal response (43% vs. 32%; odds ratio, 1.6; 95% confidence interval [CI], 1.0 to 2.3; P = 0.03) and a complete renal response (30% vs. 20%; odds ratio, 1.7; 95% CI, 1.1 to 2.7; P = 0.02). The risk of a renal-related event or death was lower among patients who received belimumab than among those who received placebo (hazard ratio, 0.51; 95% CI, 0.34 to 0.77; P = 0.001). The safety profile of belimumab was consistent with that in previous trials. CONCLUSIONS: In this trial involving patients with active lupus nephritis, more patients who received belimumab plus standard therapy had a primary efficacy renal response than those who received standard therapy alone. (Funded by GlaxoSmithKline; BLISS-LN ClinicalTrials.gov number, NCT01639339.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2001180

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 7

  1. 10.2174/1574887112666171123113200 · doi:10.2174/1574887112666171123113200
  2. 10.1155/2013/954292 · doi:10.1155/2013/954292
  3. 10.1177/0961203317717083 · doi:10.1177/0961203317717083
  4. 10.1136/lupus-2017-000213 · DOI
  5. 10.1186/s13075-015-0621-6 · DOI
  6. 10.1136/annrheumdis-2020-eular.2983 · doi:10.1136/annrheumdis-2020-eular.2983
  7. 10.1681/ASN.2006090992 · doi:10.1681/asn.2006090992

Cited by

See all 1,032

Metadata

Authors
Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., Saxena, A., Green, Y., Ji, B., Kleoudis, C., Burriss, S. W., Barnett, C., & Roth, D. A.
Venue
New England Journal of Medicine
Published
2020-09-17
Volume
383
Issue
12
Pages
1117-1128
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3085025551
Cited by
1,032
References
33
FWCI
81.52
Type
journal article
Language
en
Open access
bronze
Funders
GSK (GSK Study 114054)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.